The company reported ($0.71) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.36), Zacks reports. BTIG Research cut Organogenesis from a “buy” rating to a “neutral” rating in a report on Friday, May 8th. Mercer Global Advisors Inc. ADV purchased a new position in shares of Organogenesis during the fourth quarter worth $57,000. Finally, Oxford Asset Management LLP acquired a new stake in shares of Organogenesis in the fourth quarter valued at $66,000. Organogenesis Company Profile(Get Free Report)Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine.